The Infectious Diseases Society of America and its HIV Medicine Association endorse the measures to control the spread of COVID-19 called for by the Trump administration Monday.
The Infectious Diseases Society of America and its HIV Medicine Association endorse the measures to control the spread of COVID-19 called for by the Trump administration Monday.
The Families First Coronavirus Response Act (H.R. 6201) represents swift action by the House of Representatives to bolster federal responses to the spread of coronavirus and aims to reduce the pandemic’s impacts on Americans’ safety and financial security.
As international and federal health officials have noted this week, the accelerated spread of COVID-19 calls for greatly intensified responses everywhere to the immediate threat of worldwide epidemics of the disease, and to the looming threat of a pandemic.
President Trump’s proposed fiscal year 2021 budget cuts funding for many large-scale health programs and federal agencies, potentially leaving the United States vulnerable to infectious disease outbreaks.
Today’s declaration by the World Health Organization that the spread of a novel coronavirus constitutes a Public Health Emergency of International Concern is a pivotal step in ensuring a coordinated and comprehensive response to the outbreak.
The National Academy of Medicine report released Thursday, Opportunities to Improve Opioid Use Disorder and Infectious Disease Services: Integrating Responses to a Dual Epidemic,
The first U.S. patient to be diagnosed with the novel coronavirus first reported in Wuhan, China highlights needs for expanded readiness to detect, prevent and respond to this virus and those to come, at home and abroad.
The IDSA Board of Directors has added ten members to those receiving the Fellow of IDSA Designation. FIDSA is the ID profession’s highest honor given to those who demonstrate excellence and leadership in the field. See the full list of 2019 FIDSA designees.
The bankruptcy filing announced today by antibiotic maker Melinta once again highlights the daunting challenges facing research and development of new infection-fighting drugs.
The spending bill passed today is a welcome step forward. Allocations in the bill will strengthen public health and research efforts during the year ahead and will provide critical support for important goals.
H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act passed by the House of Representatives today introduces critically needed and significant steps to reduce costs and improve access to life-saving therapies for conditions including HIV and hepatitis C.
Today’s subcommittee hearing on U.S. preparedness and responses for the 2019-2020 flu season offers an important opportunity to examine and act on gaps and challenges exacerbating the public health threats of seasonal influenza outbreaks.